CDNF in patients

Our CDNF is a novel drug candidate that has the potential to stop the progression of Parkinson’s disease by protecting neurons from degeneration and restoring the functions of already damaged neurons. CDNF is currently in Phase 1-2 randomized, placebo-controlled, double-blind, multicenter clinical study in three university hospitals in Sweden and Finland for the treatment of Parkinson’s disease. The patient recruitment has been closed in the ongoing Phase 1-2 clinical study. More information about the clinical study is available at treater.eu. Any concrete plans for further clinical studies will be announced on our web site.

Parkinson’s disease

Parkinson’s disease is an incurable, progressive brain disorder estimated to affect over seven million patients worldwide. It is caused by the degeneration of dopamine-producing neurons in the brain. The full mechanism behind the degeneration is not fully understood yet. It is however known that the accumulation and aggregation of alpha-synuclein in those neurons is at the core of the disease, and that the neuronal degeneration is associated with a cell level phenomenon called ER stress. The typical symptoms of the disease include tremors, slowness of movement, muscle stiffness, and impaired balance. As the disease progresses, other possible symptoms include sleep problems, depression, speech changes, and severe constipation.

About CDNF

The drug candidate CDNF is a natural human protein, which has been shown to protect neurons, and help degenerating neurons restore their functionality. This is based on several mechanisms, including alleviation of ER stress and reduction of alpha-synuclein aggregation. Both are highly relevant to Parkinson’s disease.

In Parkinson’s disease models, CDNF restores the function of already damaged neurons and protects healthy neurons from degeneration. Based on this, CDNF has the potential to alleviate both motor and non-motor symptoms of Parkinson’s disease as well as stop the further progression of the condition. For more detailed information on the mechanism of action of CDNF, please see here.

CDNF is administered directly in the affected area in the brain with a sophisticated drug delivery device that is implanted in a neurosurgical procedure comparable to the placement of a Deep Brain Stimulation device.

Introductory video on CDNF

CDNF in media

EU success story article about CDNF: Novel drug delivered direct to brain may halt Parkinson’s

Lymfactin® in Patients

Lymfactin® aims to become the first drug for treating secondary lymphedema. It is presently being developed for the treatment of breast cancer associated secondary lymphedema (BCAL) in patients who undergo lymph node transplantation surgery. A Phase 1 clinical study is currently in a long-term follow-up and a randomized Phase 2 clinical study is currently ongoing at 5 university hospitals in Finland and Sweden. The patient recruitment has been completed. More information about the ongoing Phase 2 study can be found at lymfactin.fi (for Finnish patients) and lymfactin.se (for Swedish patients).

We are frequently contacted by patients and physicians enquiring about the possibility to use Lymfactin® for the treatment of other lymphedemas. While we believe in the potential of Lymfactin® beyond BCAL, for ethical and regulatory reasons we are currently focused on BCAL. Any concrete plans for expansion in other lymphedemas would be announced on our web site.

Secondary lymphedema

Secondary lymphedema is caused by injuries of the lymphatic system, which can manifest as a result of cancer treatments such as surgery and radiotherapy. The injuries of the lymphatic system may result in the accumulation of lymph in tissue in areas such as the limbs. This leads to a chronic, progressive swelling.

Secondary lymphedema is a painful, deforming disease that often has a significant impact on the quality of life of the patients. Symptoms of secondary lymphedema include progressive swelling of the affected limb, pain, decreased mobility, and increased forming of connective tissue. Many patients also suffer from repeated infections of the affected tissue.

About Lymfactin®

Lymfactin® is a gene therapy that promotes the formation of new lymphatic vessels in the damaged area, to reconstitute a functional lymphatic system. This is accomplished with the natural human growth factor VEGF-C, which is necessary for the creation of new lymphatic vessels.

Lymfactin® is injected locally at the site with injuries. This is expected to stimulate the formation of new lymphatic vessels. This may eventually normalize the lymphatic flow and thereby stop the accumulation of the lymph in tissue in patients. For more detailed information on the mechanism of action please see here.

Introductory video on Lymfactin®

Parkinson’s disease patients

The Finnish Parkinson Association
European Parkinson’s Disease Association EPDA – Herantis Pharma is a funding partner of EPDA
American Parkinson’s Disease Association APDA
Michael J. Fox Foundation

Lymphedema patients

Lymphatic Education and Research Network, LE&RN – Herantis Pharma is a Corporate Partner of LE&RN